BioCorRx (OTC:BICX) announced this month that it won a two-year grant from the NIH’s National Institute on Drug Abuse to support the development of its sustained release naltrexone implant for the treatment of opioid use disorder.
The grant includes $2.8 million for Feb. 1, 2019 to Jan. 31, 2020, followed by $2.8 million for the second year based on the project’s progress.
Get the full story at our sister site, Drug Delivery Business News.
The post BioCorRx wins $5.6m grant for sustained release naltrexone implant appeared first on MassDevice.